Boehringer Ingelheim partnered with Capgemini Invent to develop a custom NLP-driven analytics platform aimed at utilizing unstructured data, such as clinical trial results and social media insights. The platform, built through a collaborative design process, leverages AI and machine learning to automate insights and improve data-driven decision-making. Key benefits include a 40% reduction in response time for complex medical inquiries and €1.5 million in projected annual financial gains. The platform has enhanced company-wide access to valuable data, transforming Boehringer Ingelheim’s operations and positioning them as an industry innovator.

Join for free to read